Mergers and acquisitions in the life sciences were rampant this past year – highlighted, of course, in that monster of a buyout between Allergan and Pfizer. We have every reason to believe that this M&A trend will continue well into 2016.
But while we can undoubtedly expect big pharma to acquire therapeutics startups, and medical device giants to gobble medical device peons, we have a flair for the unexpected. So here’s a list of some unconventional – but potentially profitable – M&A activity in the life sciences (and beyond).
